IDEXX Laboratories stock
IDXXNASDAQIDEXX Laboratories, Inc., HealthcareISIN US45168D1046
79Score 79 out of 100, Strong
Price and trend
72 / 100
Price history
−2.2% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 22% above it.
Since March 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 74).
The price is 9.0% below its 52-week high. Largest decline in 20 years: 72% (April 2007 to June 2007).
Chart figures for advanced users
- SMA 50$558.91
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$572.21
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)74
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$504.70
- The lowest closing price of the last twelve months.
- Resistance$766.68
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- IDEXX Laboratories, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $54.99B, is number 4 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.3B (up 10.4% year on year) and earnings of $1.06B (up 19.3%).
- For fiscal 2026, analysts expect on average revenue of $4.75B (up 10.3%) and adjusted earnings per share of $14.87 (up 13.8%).
Show more
- MEQIRI Score 79 out of 100 (Strong): rank 27 of 702 in Healthcare, median 53.
- The P/E is 46.7 (Medical (Diagnostics & Research) median 33.7, own median of recent years 51.7).
- Our model puts fair value at $455.61, with the price 53% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 45.4% in fiscal 2025, Medical (Diagnostics & Research) median 6.4%.Profitability 97
- High marginNet margin 25.4% over the last 12 months, Medical (Diagnostics & Research) median 6.7%.Profitability 97
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 97
Weaknesses
- Above fair valuePrice 53% above the fair value of $455.61.Valuation 21
Its standout strengths are fundamentals and profitability, while valuation holds the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $350.47 and expensive above $650.87 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $407.68 (cash-flow model) and $503.54 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.1%. At 10.1% the fair value would be $421.02, at 8.1% it would be $506.47.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (33.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 11.9% on the twelve months before. Revenue has grown solidly since 2006, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 62%, operating 32%, net 25%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 1 Feb 2027in 80 days
- Last reported
- 2 Nov 2026EPS reported $3.96 (expected $3.73)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $14.87+0.8%
- Revenue
- $4.75B+0.5%
- Earnings per share
- $16.82+0.4%
- Revenue
- $5.16B+0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +3.0%2026 guidance raised: revenue $4.70 billion to $4.745 billion, organic growth 8.5% to 9.7%, EPS $14.69 to $14.94 (up $0.14 at the midpoint).
“We're also increasing our full year EPS outlook to $14.69 to $14.94 per share, an increase of $0.14 per share at midpoint, reflecting a 13% to 15% comparable EPS growth range.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 4 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $28.57M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at IDEXX Laboratories
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 79
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- Thermo Fisher ScientificTMO $259.15B68
- DanaherDHR $163.33B66
- WuXi AppTec603259.SS $68.42B85
- Agilent TechnologiesA $48.78B76
- NateraNTRA $46.83B43
- WatersWAT $45.38B55
- IQVIA HoldingsIQV $44.68B67
- Mettler-Toledo InternationalMTD $34.43B76
ETFs that hold IDEXX Laboratories
Held by 133 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Harbor Health Care UCITS ETF AccW311 | 3.03% | 0.89% | €11.72M |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 1.95% | 0.18% | €839.61M |
| Amundi US Tech 100 Equal Weight UCITS ETF DR USDWEBA | 1.51% | 0.07% | €342.33M |
Show 5 more
| Amundi MSCI World SRI Climate Paris Aligned UCITS ETF Acc EUR HedgedMWSH | 0.85% | 0.20% | €4.07B |
| UBS Factor MSCI USA Prime Value Screened UCITS ETF USD disUBUS | 0.83% | 0.25% | €130.8M |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.81% | 0.12% | €1.39B |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.81% | 0.15% | €3.29B |
| UBS Factor MSCI USA Quality Screened UCITS ETF USD disUBUT | 0.81% | 0.25% | €1.16B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Oct 2022)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.